[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometriosis-related-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometriosis-related-pain":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,74,112,133,185,209,234,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100560583","the-heroes-trial-hyperbaric-oxygen-therapy-for-endometriosis-related-pain-100560583",false,"NCT06579040","The HEROES Trial: Hyperbaric Oxygen Therapy for Endometriosis-Related Pain","The HEROES Trial: Hyperbaric Oxygen Therapy for Endometriosis-Related Pain: A Prospective Randomized Study","HEROES","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patients having refractory pelvic pain (NRS≥4) secondary to endometriosis for \\>6 months\n* May or may not be on traditional multi-modal treatment (pharmacological and\u002For non-pharmacological)\n* On waitlist for surgical treatment\n\nExclusion Criteria:\n\n* Patients with chronic pain resulting from disease processes unrelated to the pathophysiology of endometriosis-related symptoms (e.g. irritable bowel syndrome, migraine headache, fibromyalgia, chronic low back pain, and musculoskeletal injuries)\n* Contraindications\u002Fmedically unfit to receive hyperbaric treatments at an outpatient facility (e.g. pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)\n* Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)","ALL","18 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","Endometriosis, is a condition where tissue from the uterus, called endometrium, grows outside of the uterus. This effects up to 10% of women, and can lead to long-lasting, moderate to severe pelvic pain, infertility and other symptoms. This can affect a woman's quality of life (including increased risk of depression and anxiety) and is associated with increased healthcare costs.\n\nCurrent treatments are often limited by serious side effects, and many women resort to surgery. Surgery is also associated with complications and there are long wait times for procedures, sometimes over 3 years. This means that many women continue to suffer from symptoms while they wait for surgery. Therefore, new effective treatments for endometriosis pain are needed.\n\nNew research suggests that inflammation and stress caused by lack of oxygen in the affected areas may cause endometriosis. Hyperbaric Oxygen Therapy (HBOT), where patients are placed in a small chamber with higher than normal levels of oxygen, suppresses inflammation and promotes tissue healing. Because inflammation is central to this condition, HBOT has emerged as a potential treatment.\n\nIn this study, the investigators will test if HBOT, in addition to the standard treatments, is more effective at treating endometriosis pain than the standard treatments alone.",[27],"Endometriosis-related Pain",[29,27,30,31],"Endometriosis","Hyperbaric Oxygen Therapy","HBOT","RECRUITING","2026-04-10",{"date":35,"type":36},"2026-04-15","ACTUAL",{"date":38,"type":36},"2025-04-08",{"date":40,"type":21},"2027-12",{"name":42,"class":43},"Sunnybrook Health Sciences Centre","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100632699","intraoperative-sono-assessment-in-deep-endometriosis-100632699","NCT07517081","Intraoperative Sono-assessment In Deep Endometriosis","Intraoperative Ultrasound in Rectal Shaving for Deep Infiltrating Endometriosis: Evaluation of Residual Disease, Bowel Wall Thickness, and Clinical Outcomes","INSIDE","Inclusion Criteria:\n\n* Female patients aged 20-60 years\n* Rectal or sigmoid nodule with muscularis propria infiltration ≥1 mm and \\\u003C20 mm (assessed by expert transvaginal ultrasound)\n* Indication for surgery agreed upon with the patient\n* Written informed consent\n\nExclusion Criteria:\n\n* Previous major bowel surgery or primary indication for bowel resection\n* Inflammatory bowel disease, malignancy, or severe pelvic pathology\n* Inability to complete study questionnaires","FEMALE","20 Years","60 Years",{"count":57,"type":21},57,"OBSERVATIONAL","Deep infiltrating endometriosis (DIE) involving the bowel, particularly the rectosigmoid region, is associated with significant gastrointestinal symptoms and impaired quality of life. Rectal shaving is a conservative surgical technique aimed at removing endometriotic lesions while preserving bowel integrity; however, it may result in residual disease or excessive thinning of the bowel wall, potentially leading to recurrence or complications.\n\nIntraoperative ultrasound (IOUS) allows real-time assessment of residual nodule thickness and bowel wall thickness after shaving. This prospective observational study aims to evaluate the relationship between intraoperative ultrasound measurements and postoperative clinical outcomes, including gastrointestinal symptoms and quality of life.\n\nThe study also seeks to identify ultrasound cut-off values that may guide intraoperative surgical decision-making and optimize the balance between radicality and safety.",[29,27,61,62,63],"Pelvic Pain Syndrome","Endometriosis, Rectum","Endometriosis of Colon","NOT_YET_RECRUITING","2026-04-01",{"date":67,"type":36},"2026-04-08",{"date":69,"type":21},"2026-04-07",{"date":71,"type":21},"2028-07-07",{"name":73,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":97,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":44},"100577203","efficacy-of-physical-therapy-treatment-in-endometriosis-and-its-relationship-to-adherence-rates-100577203","NCT06795243","Efficacy of Physical Therapy Treatment in Endometriosis and Its Relationship to Adherence Rates.","Inclusion Criteria:\n\n* Adult women (over 18 years of age) diagnosed with endometriosis.\n* Women with the capacity to carry out a therapeutic program based on muscular exercise.\n* Women with the capacity to understand the requirements of the study.\n\nExclusion Criteria:\n\n* Women undergoing fertility and\u002For assisted reproduction treatment.\n* Pregnant women.",{"count":81,"type":21},32,[24],"The main objective of this study is to know if the application of both therapies, neuroscience pain education plus therapeutic exercise will modify pain, catastrophizing and quality of life in endometriosis.",[29,85,86,27,87,88,89,90,91,92,93,94,95,96],"Endometriosis Related Pain","Endometriosis, Pain","Pain","Pain Intensity Assessment","Pain Management","Pain, Chronic Disease","Pain Score","Therapeutic Exercise","Exercise Adherence","Adherence, Treatment","Treatment Adherence and Compliance","Quality of Life",[29,85,86,87,88,89,98,99,100,101,94,95,102],"Pain, chronic disease","pain score","therapeutic exercise","exercise adherence","Quality of life","2026-03-30",{"date":105,"type":36},"2026-04-06",{"date":107,"type":36},"2025-05-01",{"date":109,"type":21},"2026-07-01",{"name":111,"class":43},"University of Seville",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100626777","relugolix-for-endometriosis-associated-pain-100626777","NCT07440043","Relugolix for Endometriosis Associated Pain","An Ambispective, Single-center Observational Study Evaluating the Effectiveness of Relugolix Combination Therapy in Reducing Endometriosis-associated Pain Over 24 Weeks in a Real-world Clinical Setting","RELAX","Inclusion Criteria:\n\n* Female aged between 18 and 50 years\n* Endometriosis confirmed laparoscopically or radiologically (via ultrasound or MRI)\n* Receiving treatment with Relugolix CT according to clinical practice for at least one month\n* Pain score ≥40 on the VAS scale\n* Regular menstrual cycles, (i.e., not in a menopausal or perimenopausal state)\n* Signed informed consent\n\nExclusion Criteria:\n\n\\- Menopausal status (natural or surgical)","50 Years",{"count":122,"type":21},33,"Endometriosis is a chronic, estrogen-dependent condition frequently associated with pelvic pain and reduced quality of life. Relugolix combination therapy (CT), an oral GnRH receptor antagonist-based treatment, has demonstrated efficacy in randomized clinical trials, but real-world data remain limited.\n\nThe RELAX study is a single-center, ambispective observational study evaluating the effectiveness of relugolix CT in reducing endometriosis-associated pain over 24 weeks in routine clinical practice. The primary endpoint is the change from baseline in pelvic pain measured by the Visual Analog Scale (VAS). Secondary outcomes include changes in pain-related symptoms, ultrasonographic findings, patient satisfaction, and safety.",[29,27,61],"2026-02-23",{"date":127,"type":36},"2026-02-27",{"date":129,"type":21},"2026-02-25",{"date":131,"type":21},"2027-02-28",{"name":73,"class":43},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":142,"conditions":143,"keywords":166,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":44},"100497203","assessing-symptom-and-mood-dynamics-in-pain-using-the-smartphone-application-soma-100497203","NCT05754190","Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","INCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week or\n  * Average pain interference score of greater than 3 in the past week or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: greater than 6 months\n* Acute pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week\n\n    ○ or\n  * Average pain interference score of greater than 3 in the past week\n\n    ○ or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: less than 3 months\n  * Pain cause: Due to recent surgery, injury, acute illness, or childbirth (within the past 3 months)\n* Healthy control group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of less than 3 in the past week\n  * Average pain interference score of less than 3 in the past week\n  * Average pain distress score of less than 3 in the past week\n  * No surgery, injury, acute illness, or childbirth (within the past 3 months)\n* In person EEG testing \\[Sub-Study only\\]:\n\n  * Same as in General App Study Above and additionally:\n  * Current diagnosis of Fibromyalgia, Chronic Low Back Pain or Failed Back Surgery Syndrome OR\n  * No current or prior history of chronic pain\n  * If participant has chronic low back pain or failed back surgery syndrome: are they planning to have either a radio-frequency ablation, back surgery, or spinal cord stimulation implant in the next few months\n  * If participant has chronic low back pain or failed back surgery syndrome: have they received insurance approval for the procedure?\n  * Ok with EEC\u002FECG measures\n\nEXCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * recent injury or surgery unrelated to the pain in the past 3 months\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Acute pain group:\n\n  * History of Chronic Pain (Pain lasting for more than 6 months)\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Healthy control group:\n\nHistory of Chronic Pain (Pain lasting for more than 6 months)\n\n* difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n* Not fluent in English (difficulty understanding questions)\n\n  -In person EEG testing \\[Sub-study only\\]: \\[will interfere with EEG data collection safety or quality\\]:\n* Same as in General App Study Above and additionally:\n* Baldness\n* Pregnancy\n* Dreadlocks\n* Left-handedness\n* Use of a wheelchair\n* Heart failure diagnosis\n* Current or prior experience with acute psychosis or mania\n* implanted pacemaker, neurostimulator or any other head or heart implants\n* require a hearing aid to hear properly\n* claustrophobia\n* metal fragments in the body",true,{"count":141,"type":21},800,"This study relies on the use of a smartphone application (SOMA) that the investigators developed for tracking daily mood, pain, and activity status in acute pain, chronic pain, and healthy controls over four months.The primary goal of the study is to use fluctuations in daily self-reported symptoms to identify computational predictors of acute-chronic pain transition, pain recovery, and\u002For chronic pain maintenance or flareups. The general study will include anyone with current acute or chronic pain, while a smaller sub-study will use a subset of patients from the chronic pain group who have been diagnosed with chronic low back pain, failed back surgery syndrome, or fibromyalgia. These sub-study participants will first take part in one in-person EEG testing session while completing simple interoception and reinforcement learning tasks and then begin daily use of the SOMA app. Electrophysiologic and behavioral data from the EEG testing session will be used to determine predictors of treatment response in the sub-study.",[144,145,146,147,148,149,150,151,152,153,154,27,155,156,157,158,159,160,161,162,163,164,165],"Chronic Pain","Acute Pain","Post Operative Pain","Fibromyalgia, Primary","Fibromyalgia, Secondary","Fibromyalgia","Irritable Bowel Syndrome","Chronic Headache Disorder","Chronic Migraine","Chronic Pelvic Pain Syndrome","Temporomandibular Joint Disorders","Arthritis","Chronic Low-back Pain","Failed Back Surgery Syndrome","Post Herpetic Neuralgia","Neuropathic Pain","Painful Diabetic Neuropathy","Painful Bladder Syndrome","Trauma-related Wound","Trauma, Multiple","Chronic Pain Syndrome","Chronic Shoulder Pain",[167,168,169,170,171,172,173,174,175],"digital health","e-health","smartphone application","chronic pain","acute pain","symptom tracking","experience sampling methodology","ecological momentary assessment","pain self-management","2025-09-16",{"date":178,"type":36},"2025-09-19",{"date":180,"type":36},"2023-06-20",{"date":182,"type":21},"2026-05-30",{"name":184,"class":43},"Brown University",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":44},"100590112","phase-2-a-phase-iia-clinical-study-to-assess-the-efficacy-and-safety-of-gensci048-in-patients-with-moderate-to-severe-endometriosis-associated-pain-100590112","NCT06963177","A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain","Inclusion Criteria:\n\n1. Pre-menopausal female participants, between 18 and 49 years of age, inclusive, at the time of signing informed consent.\n2. Participants must have a diagnosis of endometriosis within 10 years before screening.\n3. Have moderate to severe endometrial related pain.\n4. Have at least one regular, natural menstrual cycles (ranging from 21 to 35 days (inclusive)) before and during the screening period.\n5. Agree to switch from her usual analgesic medication to only that which is permitted in the study from the screening period to the end of treatment and agree to stop using other treatments for endometriosis.\n6. Agree to use non-hormonal contraception from the time of signing the informed consent until 4 weeks after the last dose of the study medication.\n\nExclusion Criteria:\n\n1. Participants who have previously received hysterectomy and\u002For bilateral oophorectomy, or plan to undergo these procedures during the study period.\n2. Participants who suffer from chronic pelvic and\u002For non-pelvic pain that is not caused by EM and require chronic analgesia or other chronic treatment, which is expected to affect the assessment of EAP.\n3. Pelvic ultrasound screening indicating a need for surgery or suspicion of malignancy.\n4. Participants with abnormal and undiagnosed vaginal and\u002For uterine bleeding within 3 months prior to screening.\n5. Participants who plan to schedule elective surgery during the study; or those who have had a surgery within 4 months prior to screening and need ongoing pain management.\n6. History of severe depression or post-traumatic stress disorder within the two years prior to screening, or history of any other severe mental disorder at any time.\n7. History of drug or alcohol abuse within the six months prior to screening.\n8. Participants who have participated in any other interventional clinical trial (including clinical trials of drugs and devices) within 1 month prior to screening.\n9. Have used a prohibited long-acting anesthetic or immediate-release anesthetic for more than 2 consecutive weeks for the treatment of endometriosis associated pain in the 6 months prior to screening.\n10. Participant is pregnant, breast feeding, or planning a pregnancy.","49 Years",{"count":194,"type":21},200,[196],"PHASE2","This study is designed to evaluate the safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain treatment.",[27],"2025-08-07",{"date":201,"type":36},"2025-08-12",{"date":203,"type":36},"2025-05-26",{"date":205,"type":21},"2030-01-06",{"name":207,"class":208},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":222,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":44},"100450958","transcutaneous-electrical-nerve-stimulation-for-endometriosis-related-chronic-pain-100450958","NCT05152264","Transcutaneous Electrical Nerve Stimulation for Endometriosis-related Chronic Pain","High Frequency, High Intensity Transcutaneous Electrical Nerve Stimulation for Endometriosis-related Chronic Pain - a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years\n* Consents to participation in the study\n* Verified endometriosis (by laparoscopy or ultrasound).\n* Chronic endometriosis-related pain (\\> 3 months), available for TENS treatment\n* Functioning, stable endometriosis-specific hormonal drug therapy. The endometriosis-specific drug therapy must be unchanged for the last 3 months and no gynecological surgical procedures for the treatment of endometriosis are planned during the next 7 months (during study participation). The endometriosis-specific drug therapy does not refer to analgesic therapy for symptom relief of endometriosis-related pain.\n\nExclusion Criteria:\n\n* Patient with inability to understand and use written and spoken Swedish\n* Patient with pacemaker and\u002For ICD or other electronic implants\n* Patient with impaired sensation over the painful area\n* Malignant disease with an expected survival \\\u003C12 months\n* Alcohol or substance abuse\n* Serious untreated psychiatric illness and\u002For psychological condition that is the primary determinant of the patient's condition\n* Participating in another intervention study with possible impact on current study outcome measures\n* Patient who is using \\>90 morphine equivalents\u002Fday\n* Patient who is electro-acupuncture\n* Pregnancy","100 Years",{"count":218,"type":21},40,[24],"The study evaluates the effect of TENS (transcutaneous electrical nerve stimulation) as add-on treatment compared with conventional analgesic treatment in patients with endometriosis-related chronic pain. Patients with frequent pain and high pain intensity will be randomized to additional treatment with TENS or conventional treatment for 8 weeks to evaluate the acute effects of TENS treatment (n=40). Patients with endometriosis-related pain that is not frequent or without high pain intensity constitute an external control group. All patients in the study will receive TENS treatment for a total of 16 weeks, for evaluation of long-term effects of TENS treatment.",[27],[29,223,224],"Chronic pain","Transcutaneous electrical nerve stimulation","2025-05-20",{"date":227,"type":36},"2025-05-23",{"date":229,"type":36},"2021-11-12",{"date":231,"type":21},"2028-12",{"name":233,"class":43},"Göteborg University",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":55,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":44},"100514432","functional-links-between-the-temporomandibular-joint-and-the-pelvis-in-gynecology-100514432","NCT05978414","Functional Links Between the Temporomandibular Joint and the Pelvis in Gynecology","Functional Relationships Between the Temporomandibular Joint and the Pelvis in Women With Gynecological Diseases of Genital Prolapse and Endometriosis","TMJ and Pelvis","Inclusion Criteria:\n\n1. Written consent to participate in the study.\n2. Female patients after surgical treatment with prolapse of reproductive organs and diagnosed endometriosis.\n\nExclusion Criteria:\n\n1. No written consent to participate in the study.\n2. Cancer.\n3. Injury to the temporomandibular joint and pelvis.\n4. Fibromyalgia.\n5. Rheumatic diseases.\n6. At each stage of the experiment if the patient decides that she does not want to participate she is excluded.",{"count":194,"type":21},[24],"1 Recruitment. 2. Collection of written consents for the study. 3. Random assignment to groups with and without intervention. 4. Completion of questionnaires by study participants, postural pattern assessment, temporomandibular joint assessment, and platform assessment.\n\n5\\. Performance of visceral therapy in the group with intervention, in the group without intervention placebo. Duration 5 weeks, treatment 1x per week at the same time of day and given day e.g. Mondays only.\n\n6\\. Reassessment as in step 4. 7. Data collection, statistical analyses. 8. Interpretation of results for female participants. 9. Preparation of results for scientific publications.",[246,27],"Prolapse; Female",[248,249,250,251,252,253],"quaity of life","women","prolapse; female","endometriosis-related pain","visceral therapy","temporomandibular joint","2025-02-05",{"date":256,"type":36},"2025-02-07",{"date":258,"type":36},"2023-11-14",{"date":260,"type":21},"2026-09-01",{"name":262,"class":43},"Poznan University of Physical Education",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":44},"100547908","histologic-comparison-of-ablative-techniques-for-endometriosis-100547908","NCT06414083","Histologic Comparison of Ablative Techniques for Endometriosis","Histologic Comparison of Ablative Techniques for Endometriosis - a Randomized Trial","Inclusion Criteria:\n\n* Adult women 18 years of age or older\n* Already planning to undergo scheduled robotic assisted or laparoscopic excision of lesions for pelvic pain symptoms (pelvic pain, dysmenorrhea, dyspareunia, dysuria, dyschezia, ovarian pain) or endometriosis of any kind (endometriosis of any location, or endometrioma)\n\nExclusion Criteria:\n\n* Known pregnancy at enrollment or at the time of the excision surgery",{"count":271,"type":21},141,[24],"To our knowledge, no other human studies directly compare the effectiveness of the various ablative technologies. We set out to design a study to directly compare ablative energy sources and evaluate their ability to destroy native endometriosis tissue in humans.",[29,27,275,276],"Endometriosis Pelvic","Endometriosis; Peritoneum","2024-05-28",{"date":279,"type":36},"2024-05-30",{"date":281,"type":36},"2024-05-09",{"date":283,"type":21},"2025-06-09",{"name":285,"class":43},"TriHealth Inc."]